Want to see JP:4564 full AI Analyst Report?

OncoTherapy Science (4564) Ratios

2 Followers

OncoTherapy Science Ratios

JP:4564's free cash flow for Q4 2024 was ¥0.06. For the 2024 fiscal year, JP:4564's free cash flow was decreased by ¥ and operating cash flow was ¥-0.62. See a summary of the company’s cash flow.

Ratios	TTM	Mar 26	Mar 25	Mar 24	Mar 22
Liquidity Ratios
Current Ratio	―	13.59	3.37	2.27	2.33
Quick Ratio	―	13.22	3.13	2.07	2.17
Cash Ratio	―	12.29	2.54	1.47	1.83
Solvency Ratio	―	-4.19	-0.04	-2.51	-1.68
Operating Cash Flow Ratio	―	-5.43	-2.49	-3.41	-1.30
Short-Term Operating Cash Flow Coverage	―	0.00	0.00	0.00	0.00
Net Current Asset Value	¥ ―	¥ 2.09B	¥ 679.61M	¥ 304.16M	¥ 765.99M
Leverage Ratios
Debt-to-Assets Ratio	―	0.00	0.04	0.12	0.00
Debt-to-Equity Ratio	―	0.00	0.07	0.30	0.00
Debt-to-Capital Ratio	―	0.00	0.07	0.23	0.00
Long-Term Debt-to-Capital Ratio	―	0.00	0.07	0.23	0.00
Financial Leverage Ratio	―	1.10	1.58	2.45	1.77
Debt Service Coverage Ratio	―	-619.79	-677.84	-5.91K	0.00
Interest Coverage Ratio	―	-618.14	-664.39	-5.14K	0.00
Debt to Market Cap	―	0.00	<0.01	0.03	0.00
Interest Debt Per Share	―	<0.01	0.20	0.50	0.00
Net Debt to EBITDA	―	2.58	0.96	0.33	1.02
Profitability Margins
Gross Profit Margin	―	1.73%	-1.70%	-29.13%	3.67%
EBIT Margin	―	-100.23%	-108.25%	-210.70%	-98.37%
EBITDA Margin	―	-100.23%	-108.25%	-210.70%	-96.13%
Operating Profit Margin	―	-100.23%	-106.38%	-183.70%	-97.49%
Pretax Profit Margin	―	-112.36%	-108.41%	-210.73%	-98.37%
Net Profit Margin	―	-112.63%	-108.70%	-211.13%	-98.57%
Continuous Operations Profit Margin	―	-112.63%	-108.70%	-211.13%	-98.57%
Net Income Per EBT	―	100.24%	100.27%	100.19%	100.20%
EBT Per EBIT	―	112.10%	101.90%	114.71%	100.90%
Return on Assets (ROA)	―	-38.60%	-70.58%	-148.53%	-74.01%
Return on Equity (ROE)	―	-42.51%	-111.82%	-364.22%	-130.81%
Return on Capital Employed (ROCE)	―	-37.01%	-96.43%	-220.77%	-122.63%
Return on Invested Capital (ROIC)	―	-37.01%	-96.43%	-220.77%	-122.63%
Return on Tangible Assets	―	-38.60%	-70.58%	-148.53%	-74.01%
Earnings Yield	―	-13.21%	-11.15%	-30.27%	-12.35%
Efficiency Ratios
Receivables Turnover	―	7.81	7.59	3.23	9.22
Payables Turnover	―	0.00	0.00	0.00	0.00
Inventory Turnover	―	12.73	9.67	10.65	10.97
Fixed Asset Turnover	―	0.00	0.00	0.00	0.00
Asset Turnover	―	0.34	0.65	0.70	0.75
Working Capital Turnover Ratio	―	0.55	1.21	0.96	0.81
Cash Conversion Cycle	―	75.43	85.85	147.41	72.85
Days of Sales Outstanding	―	46.74	48.11	113.13	39.59
Days of Inventory Outstanding	―	28.68	37.74	34.28	33.26
Days of Payables Outstanding	―	0.00	0.00	0.00	0.00
Operating Cycle	―	75.43	85.85	147.41	72.85
Cash Flow Ratios
Operating Cash Flow Per Share	―	-2.81	-3.12	-5.77	-4.13
Free Cash Flow Per Share	―	-3.00	-3.12	-5.78	-4.15
CapEx Per Share	―	0.19	<0.01	0.01	0.03
Free Cash Flow to Operating Cash Flow	―	1.07	1.00	1.00	1.01
Dividend Paid and CapEx Coverage Ratio	―	-14.83	-2.92K	-467.45	-147.39
Capital Expenditure Coverage Ratio	―	-14.83	-2.92K	-467.45	-147.39
Operating Cash Flow Coverage Ratio	―	0.00	-15.96	-11.49	0.00
Operating Cash Flow to Sales Ratio	―	-1.14	-1.09	-2.01	-0.70
Free Cash Flow Yield	―	-14.29%	-11.15%	-28.92%	-8.84%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-7.58	-8.97	-3.30	-8.09
Price-to-Sales (P/S) Ratio	―	8.53	9.75	6.98	7.98
Price-to-Book (P/B) Ratio	―	3.22	10.03	12.03	10.59
Price-to-Free Cash Flow (P/FCF) Ratio	―	-7.00	-8.97	-3.46	-11.31
Price-to-Operating Cash Flow Ratio	―	-7.47	-8.97	-3.47	-11.39
Price-to-Earnings Growth (PEG) Ratio	―	0.68	0.19	-0.80	0.14
Price-to-Fair Value	―	3.22	10.03	12.03	10.59
Enterprise Value Multiple	―	-5.93	-8.04	-2.98	-7.27
Enterprise Value	―	4.80B	6.53B	3.83B	7.94B
EV to EBITDA	―	-5.93	-8.04	-2.98	-7.27
EV to Sales	―	5.94	8.71	6.29	6.99
EV to Free Cash Flow	―	-4.88	-8.01	-3.12	-9.92
EV to Operating Cash Flow	―	-5.21	-8.01	-3.12	-9.98
Tangible Book Value Per Share	―	6.53	2.79	1.66	4.44
Shareholders’ Equity Per Share	―	6.53	2.79	1.66	4.44
Tax and Other Ratios
Effective Tax Rate	―	>-0.01	>-0.01	>-0.01	>-0.01
Revenue Per Share	―	2.46	2.87	2.87	5.89
Net Income Per Share	―	-2.77	-3.12	-6.05	-5.81
Tax Burden	―	1.00	1.00	1.00	1.00
Interest Burden	―	1.12	1.00	1.00	1.00
Research & Development to Revenue	―	0.66	0.65	1.11	0.63
SG&A to Revenue	―	0.36	0.39	0.43	0.38
Stock-Based Compensation to Revenue	―	0.00	0.00	0.01	0.03
Income Quality	―	1.01	1.00	0.95	0.71

Currency in JPY